Novel tumor vaccine gp96-Ig fusion heat shock protein in advanced non-small cell lung cancer (NSCLC) patients who have failed palliative chemotherapy and erlotinib

被引：0
|
作者：
Podack, E.
Raez, L. E.
Fisher, E.
Leibovitch, E.
Gomez, J. E.
Baldie, P.
Tolba, K. A.
Santos, E. S.
Walker, G.
机构：
[1] Univ Miami, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami, Sch Med, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18042
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Quality of life and survival in patients receiving chemotherapy for advanced non-small cell lung cancer (NSCLC)
    St-Pierre, D. M.
    Kreisman, H.
    Kasymjanova, G.
    Agulnik, J. S.
    Swanson, T.
    Pepe, C.
    Lajeunesse, L.
    Gagne, S.
    Dajczman, E.
    Pereira, L.
    Small, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Impact of neutropenia on chemotherapy administration in elderly patients with advanced non-small cell lung cancer (NSCLC)
    Knopf, K. B.
    Lipscomb, J.
    Gillespie, T. W.
    Stokes, M. E.
    Muehlenbein, C. E.
    Faries, D.
    Marciniak, M. D.
    Motabar, S.
    Buesching, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer (NSCLC) palliative receiving chemotherapy.
    Vincent, M.
    Dranitsaris, G.
    Clemons, M.
    Verma, S.
    Lau, C.
    Gascon, P.
    Van Belle, S.
    Ludwig, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 493S - 493S
  • [34] EMT (Epithelial to Mesenchymal Transition) Markers and Response to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Braun, E.
    Fidler, M. J.
    Shah, N.
    Kaiser, K. A.
    Basu, S.
    Harasty, H.
    Coon, J.
    Pool, M.
    Hensing, T.
    Bonomi, P. D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S533 - S533
  • [35] Erlotinib as single agent in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and poor performance status
    Perez-Carrion, Ramon
    Dolores, Isla
    Garcia, Ramon
    Vinolas, Nuria
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Juan, Luis Marti '
    Regueiro, Pilar
    Paz-Ares, Luis
    ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [36] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Salajka, Frantisek
    Pesek, Milos
    Krejci, Jana
    Skrickova, Jana
    Zatloukal, Petr
    Koubkova, Leona
    Grygarkova, Ivona
    Hrnciarik, Michal
    Sticha, Michal
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1293 - S1294
  • [38] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [39] Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer?
    Gridelli, C
    LUNG CANCER, 2002, 38 : S45 - S50
  • [40] Palliative chemotherapy with carboplatin and oral vinorelbine in advanced non-small cell lung cancer (NSCLC) - A single centre pilot audit
    Garikipati, S.
    Mohanamurali, J.
    LUNG CANCER, 2012, 75 : S9 - S10
12345